Digest Network Come funziona
Network
/
Società
Ka
Non verificato

Kairos Pharma, Ltd

Di cosa scriviamo

BiotecnologiaFarmaceuticaOncologiaSaluteScienza

22 comunicati stampa

Guarda tutti i comunicati
20/10/2025
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
07/10/2025
Salute
Scienza
Farmaceutica
Oncologia
Eventi
Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
18/09/2025
Farmaceutica
Salute
Oncologia
Medicina - Varie
Web e Social Network
Industria
Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
11/09/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Finanza
Web e Social Network
Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
03/09/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Fiere
Industria
Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
02/09/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Web e Social Network
Eventi
Finanza
Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
16/07/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
15/07/2025
Scienza
Medicina - Varie
Sanità
Biotecnologia
Farmaceutica
Salute
Oncologia
Industria
Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
03/06/2025
Scienza
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Industria
Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0
28/04/2025
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
Fonte
Kairos Pharma, Ltd
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0